The group's principal activity is to develop and distribute urine-based diagnostic products and services. It has developed a test for the detection of antibodies to the human immunodeficiency virus, type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. The products of the group include screening enzyme immunoassay (eia) and supplemental western blot tests. The products are fda-approved HIV-1 antibody tests that can be used on urine samples. The group sells these products to community-based organizations, public health laboratories, reference laboratories and the life insurance markets located in the United States of America, Indonesia, the republic of South Africa, the People's Republic of China and Malaysia.
